Skip to content

Screening for biomarkers related to neurological outcome in patients treated endovascularly for acute ischemic stroke

Screening for biomarkers related to neurological outcome in patients treated endovascularly for acute ischemic stroke

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200057845
Enrollment
Unknown
Registered
2022-03-19
Start date
2019-12-30
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke

Interventions

None listed

Sponsors

Sun Yat-Sen Memorial Hospital Affiliated to Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Voluntary signing of the informed consent form; 2. Patients who have undergone endovascular procedures at Southern Hospital of Southern Medical University between December 2019 to September 2022; 3. Patients who visited Southern Hospital of Southern Medical University between December 2019 to September 2022, with a standardized diagnosis of acute ischemic stroke with reference to the Chinese Guidelines for Early Endovascular Interventions in Acute Ischemic Stroke 2018, and who, after diagnosis and clinical decision-making, followed the medical prescription for the proposed endovascular procedure.

Exclusion criteria

Exclusion criteria: 1. Those with a history or evidence of cerebral hemorrhage, subarachnoid hemorrhage, cranial trauma, psychiatric disease, arteriovenous malformation, cerebral aneurysm, or brain tumor; 2. Acute ST-segment elevation infarction, and/or acute decompensated heart failure, and/or QT interval >520ms, and/or known history of cardiac arrest (pulseless electrical activity, ventricular tachycardia, ventricular fibrillation, cardiac arrest), and/or admission for acute coronary syndrome, myocardial infarction, or previous coronary intervention (percutaneous coronary intervention or coronary surgery) within the past 3 months; 3. Those with combined autoimmune disease, hematologic disease, or malignancy; 4. Baseline platelet count <50,000/UL; 5. Suspected infectious emboli or suspected bacterial endocarditis; 6. Pregnant women; 7. Patients with poor compliance as judged by the physician, with anticipated difficulty in follow-up.

Design outcomes

Primary

MeasureTime frame
Modified Rankin Scale (MRS);Serological markers;

Secondary

MeasureTime frame
Malignant cerebral edema;Symptomatic hemorrhagic transformation;Deterioration of condition;

Countries

China

Contacts

Public ContactPan Suyue

Nanfang Hospital of Southern Medical University

pansuyue82@qq.com+86 13556184981

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026